GO41944: Phase 3 Study of Glofitamab with GemOx vs Rituximab with GemOx in patients with R/R DLBCL

• Research type

  Research Study

• Full title

  A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN VERSUS RITUXIMAB IN COMBINATION WITH GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE BCELL LYMPHOMA

• IRAS ID

  1003457

• Contact name

  Christopher Fox

• Contact email

  Christopher.Fox2@nuh.nhs.uk

• Eudract number

  2020-001021-31

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  20/SC/0390

• Date of REC Opinion

  23 Dec 2020

• REC opinion

  Further Information Favourable Opinion